|
1
|
Tomaszewski JJ, Uzzo RG and Smaldone MC:
Heterogeneity and renal mass biopsy: A review of its role and
reliability. Cancer Biol Med. 11:162–172. 2014.PubMed/NCBI
|
|
2
|
Farhadi A, Behzad-Behbahani A, Geramizadeh
B, Sekawi Z, Rahsaz M and Sharifzadeh S: High-risk human
papillomavirus infection in different histological subtypes of
renal cell carcinoma. J Med Virol. 86:1134–1144. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van de Weerdt BC and Medema RH: Polo-like
kinases: A team in control of the division. Cell Cycle. 5:853–864.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang G, Chen Q, Zhang X, Zhang B, Zhuo X,
Liu J, Jiang Q and Zhang C: PCM1 recruits PLK1 to the
pericentriolar matrix to promote primary cilia disassembly before
mitotic entry. J Cell Sci. 126:1355–1365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stone A, Cowley MJ, Valdes-Mora F, McCloy
RA, Sergio CM, Gallego-Ortega D, Caldon CE, Ormandy CJ, Biankin AV,
Gee JM, et al: BCL-2 hypermethylation is a potential biomarker of
sensitivity to antimitotic chemotherapy in endocrine-resistant
breast cancer. Mol Cancer Ther. 12:1874–1885. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu XS, Song B, Elzey BD, Ratliff TL,
Konieczny SF, Cheng L, Ahmad N and Liu X: Polo-like kinase 1
facilitates loss of Pten tumor suppressor-induced prostate cancer
formation. J Biol Chem. 286:35795–35800. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Song B, Liu XS, Rice SJ, Kuang S, Elzey
BD, Konieczny SF, Ratliff TL, Hazbun T, Chiorean EG and Liu X: PLK1
phosphorylation of orc2 and hbo1 contributes to gemcitabine
resistance in pancreatic cancer. Mol Cancer Ther. 12:58–68. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang G, Zhang Z and Liu Z: Polo-like
kinase 1 is overexpressed in renal cancer and participates in the
proliferation and invasion of renal cancer cells. Tumour Biol.
34:1887–1894. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Z, Zhang G and Kong C: High
expression of polo-like kinase 1 is associated with the metastasis
and recurrence in urothelial carcinoma of bladder. Urol Oncol.
31:1222–1230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Factor VM, Seo D, Ishikawa T, Kaposi-Novak
P, Marquardt JU, Andersen JB, Conner EA and Thorgeirsson SS: Loss
of c-Met disrupts gene expression program required for G2/M
progression during liver regeneration in mice. PLoS One.
5:e127392010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu ZQ and Liu X: Role for PLK1
phosphorylation of Hbo1 in regulation of replication licensing.
Proc Natl Acad Sci USA. 105:1919–1924. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tategu M, Nakagawa H, Sasaki K, Yamauchi
R, Sekimachi S, Suita Y, Watanabe N and Yoshid K: Transcriptional
regulation of human polo-like kinases and early mitotic inhibitor.
J Genet Genomics. 35:215–224. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ito Y, Miyoshi E, Sasaki N, Kakudo K,
Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et
al: Polo-like kinase 1 overexpression is an early event in the
progression of papillary carcinoma. Br J Cancer. 90:414–418. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Myatt SS, Kongsema M, Man CW, Kelly DJ,
Gomes AR, Khongkow P, Karunarathna U, Zona S, Langer JK, Dunsby CW,
et al: SUMOylation inhibits FOXM1 activity and delays mitotic
transition. Oncogene. 33:4316–4329. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ustiyan V, Wang IC, Ren X, Zhang Y, Snyder
J, Xu Y, Wert SE, Lessard JL, Kalin TV and Kalinichenko VV:
Forkhead box M1 transcriptional factor is required for smooth
muscle cells during embryonic development of blood vessels and
esophagus. Dev Biol. 336:266–279. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kalinichenko VV, Lim L, Shin B and Costa
RH: Differential expression of forkhead box transcription factors
following butylated hydroxytoluene lung injury. Am J Physiol Lung
Cell Mol Physiol. 280:L695–L704. 2001.PubMed/NCBI
|
|
17
|
Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY,
Le XF, Wong OG, Wong ES, Gomes AR, Bella L, et al: Overexpression
of forkhead box protein M1 (FOXM1) in ovarian cancer correlates
with poor patient survival and contributes to paclitaxel
resistance. PLoS One. 9:e1134782014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gormally MV, Dexheimer TS, Marsico G,
Sanders DA, Lowe C, Matak-Vinković D, Michael S, Jadhav A, Rai G,
Maloney DJ, et al: Suppression of the FOXM1 transcriptional
programme via novel small molecule inhibition. Nat Commun.
5:51652014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang L, Wang P and Chen H: Overexpression
of FOXM1 is associated with metastases of nasopharyngeal carcinoma.
Ups J Med Sci. 119:324–332. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li XR, Chu HJ, Lv T, Wang L, Kong SF and
Dai SZ: miR-342-3p suppresses proliferation, migration and invasion
by targeting FOXM1 in human cervical cancer. FEBS Lett.
588:3298–3307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ning Z, Wang A, Liang J, Xie Y, Liu J,
Feng L, Yan Q and Wang Z: USP22 promotes the G1/S phase transition
by upregulating FOXM1 expression via β-catenin nuclear localization
and is associated with poor prognosis in stage II pancreatic ductal
adenocarcinoma. Int J Oncol. 45:1594–1608. 2014.PubMed/NCBI
|
|
22
|
Fu Z, Malureanu L, Huang J, Wang W, Li H,
van Deursen JM, Tindall DJ and Chen J: Plk1-dependent
phosphorylation of FOXM1 regulates a transcriptional programme
required for mitotic progression. Nat Cell Biol. 10:1076–1082.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu D, Zhang Z and Kong CZ: High FOXM1
expression was associated with bladder carcinogenesis. Tumour Biol.
34:1131–1138. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ando K, Ozaki T, Hirota T and Nakagawara
A: NFBD1/MDC1 is phosphorylated by PLK1 and controls G2/M
transition through the regulation of a TOPOIIα-mediated
decatenation checkpoint. PLoS One. 8:e827442013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pezuk JA, Brassesco MS, Morales AG, de
Oliveira JC, de Paula Queiroz RG, Machado HR, Carlotti CG Jr, Neder
L, Scrideli CA and Tone LG: Polo-like kinase 1 inhibition causes
decreased proliferation by cell cycle arrest, leading to cell death
in glioblastoma. Cancer Gene Ther. 20:499–506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang J, Yuan C, Wu J, Elsayed Z and Fu Z:
Polo-like kinase 1-mediated phosphorylation of Forkhead box protein
M1b antagonizes its SUMOylation and facilitates its mitotic
function. J Biol Chem. 290:3708–3719. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang R, Song Y, Xu X, Wu Q and Liu C: The
expression of Nek7, FoxM1, and PLK1 in gallbladder cancer and their
relationships to clinicopathologic features and survival. Clin
Transl Oncol. 15:626–632. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dibb M, Han N, Choudhury J, Hayes S,
Valentine H, West C, Ang YS and Sharrocks AD: The FOXM1-PLK1 axis
is commonly upregulated in oesophageal adenocarcinoma. Br J Cancer.
107:1766–1775. 2012. View Article : Google Scholar : PubMed/NCBI
|
